Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
5.51
+0.07 (1.19%)
Real-time:   10:51AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.34 - 5.53
52 week 3.10 - 7.45
Open 5.49
Vol / Avg. 225,868.00/1.06M
Mkt cap 382.90M
P/E     -
Div/yield     -
EPS -0.63
Shares 69.56M
Beta 1.43
Inst. own 74%
Nov 10, 2014
Q3 2014 Progenics Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 8, 2014
Q2 2014 Progenics Pharmaceuticals Inc Earnings Release
Aug 8, 2014
Q2 2014 Progenics Pharmaceuticals Inc Earnings Call - Webcast
Jul 14, 2014
Progenics Pharmaceuticals Inc FDA's Relistor� Appeal Response Conference Call - Webcast
Jun 17, 2014
Progenics Pharmaceuticals Annual Shareholder Meeting
Jun 13, 2014
Progenics Pharmaceuticals Inc Investor Conference Call Following FDA Advisory Committee - Webcast
Jun 5, 2014
Progenics Pharmaceuticals at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -749.70% -541.49%
Operating margin -750.64% -546.68%
EBITD margin - -534.74%
Return on average assets -32.44% -44.61%
Return on average equity -43.10% -58.50%
Employees 69 -
CDP Score - -

Address

777 Old Saw Mill River Road
TARRYTOWN, NY 10591
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen, a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. In January 2013, the Company acquired Molecular Insight Pharmaceuticals, Inc.

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Robert J. Israel M.D. Executive Vice President - Medical Affairs
Age: 57
Bio & Compensation  - Reuters
Hagop Youssoufian M.D. Executive Vice President - Research & Development
Age: 57
Bio & Compensation  - Reuters
John W. Babich Ph.D. Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 61
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Senior Vice President - Operations and Portfolio Management
Age: 57
Bio & Compensation  - Reuters
Angelo W. Lovallo Jr., CPA Vice President - Finance, Treasurer
Age: 48
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 60
Bio & Compensation  - Reuters
David E. Martin J.D. General Counsel
Age: 59
Bio & Compensation  - Reuters